Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer

M.A. Pruis, W.R.R. Geurts-Giele, J.H. von der Thusen, I.C. Meijssen, W.N.M. Dinjens, J.G.J.V. Aerts, A.M.C. Dingemans, M.P. Lolkema, M.S. Paats, H.J. Dubbink

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)46-54
Number of pages9
JournalLung Cancer
Volume140
DOIs
Publication statusPublished - 1 Feb 2020

Keywords

  • amplification
  • crizotinib
  • diagnostics
  • driver mutation
  • inhibition
  • met exon 14 skipping
  • met inhibitor
  • next generation sequencing
  • non-small cell lung cancer
  • patient
  • resistance
  • resistance against cmet inhibition
  • sarcomatoid carcinoma
  • target
  • targeted therapy
  • Driver mutation
  • TARGET
  • Diagnostics
  • Targeted therapy
  • MET inhibitor
  • AMPLIFICATION
  • INHIBITION
  • MET exon 14 skipping
  • CRIZOTINIB
  • SARCOMATOID CARCINOMA
  • Next generation sequencing
  • Non-small cell lung cancer
  • Resistance against cMET inhibition
  • RESISTANCE
  • PATIENT

Cite this